Short Interest in Bioxytran, Inc. (OTCMKTS:BIXT) Decreases By 97.1%

Bioxytran, Inc. (OTCMKTS:BIXT) was the recipient of a large decline in short interest during the month of March. As of March 13th, there was short interest totaling 300 shares, a decline of 97.1% from the February 26th total of 10,300 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily volume of 1,769,827 shares, the days-to-cover ratio is presently 0.0 days. Based on an average daily volume of 1,769,827 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the company’s shares are sold short.

Bioxytran Stock Up 14.6%

BIXT traded up $0.01 during trading on Tuesday, reaching $0.05. The company had a trading volume of 210,476 shares, compared to its average volume of 405,921. The stock has a market cap of $5.51 million, a P/E ratio of -1.62 and a beta of 2.14. The business has a 50 day simple moving average of $0.05 and a 200-day simple moving average of $0.06. Bioxytran has a 52 week low of $0.03 and a 52 week high of $0.23.

Bioxytran Company Profile

Bioxytran, Inc is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.

Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release.